Re-evaluation of bioequivalence of generic drugs is one of the key research focus currently. As a means to ensure consistency of the therapeutic effectiveness of drug products, clinical bioequivalence...
![Intestinal transport of TRH analogs through PepT1: the role of in silico and in vitro modeling](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Intestinal transport of TRH analogs through PepT1: the role of in silico and in vitro modeling
The present study involves molecular docking, molecular dynamics (MD) simulation studies, and Caco-2 cell monolayer permeability assay to investigate the effect of structural modifications on...
![Enhanced Solubility and Oral Bioavailability of y-Tocotrienol Using a Self-Emulsifying Drug Delivery System (SEDDS)](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Enhanced Solubility and Oral Bioavailability of y-Tocotrienol Using a Self-Emulsifying Drug Delivery System (SEDDS)
The aim of this study was to evaluate the in vitro and in vivo performance of γ-tocotrienol (γ-T3) incorporated in a self-emulsifying drugdelivery system (SEDDS)...
![Cognigen Acquisition](https://www.simulations-plus.com/wp-content/uploads/Screen-Shot-2016-11-18-at-12.55.31-PM.png)
Cognigen Acquisition
This webinar is presented to provide details and answer questions concerning Simulations Plus' acquisition of Cognigen Corporation.
![Simulations Plus Announces Quarterly Cash Dividend](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
![Simulations Plus Provides Additional Details Regarding Cognigen Acquisition](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Provides Additional Details Regarding Cognigen Acquisition
Investor Conference Call Scheduled for Friday, July 25, at 1:15 PM PDT
![Simulations Plus to Acquire Cognigen Corporation](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Acquire Cognigen Corporation
A leading provider of clinical trial data analysis to expand company’s offerings
![Design of a General-Purpose European Compound Screening Library for EU-OPENSCREEN](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Design of a General-Purpose European Compound Screening Library for EU-OPENSCREEN
This work describes a collaborative effort to define and apply a protocol for the rational selection of a general-purpose screening library, to be used by the screening platforms affiliated with the EU-OPENSCREEN initiative.
![Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans
Biliary excretion is an important route of elimination for many drugs, yet measuring the extent of biliary elimination is difficult, invasive, and variable.
![Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI
Bile salt export pump (BSEP) inhibition has been proposed to be an important mechanism for drug-induced liver injury (DILI).
![Maximum Entropy in Drug Discovery](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Maximum Entropy in Drug Discovery
Drug discovery applies multidisciplinary approaches either experimentally, computationally or both ways to identify lead compounds to treat various diseases.
![Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir
Alisporivir is a novel cyclophilin-binding molecule with potent anti-hepatitis C virus (HCV) activity. In vitro data from human liver microsomes suggest that alisporivir is a substrate and a time-dependent inhibitor (TDI) of CYP3A4.
![Simulations Plus Reports Third Quarter FY2014 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Third Quarter FY2014 Financial Results
Revenues up 20.9%, Net Income up 31.6%
![Simulations Plus Sets Date for 3rd Quarter 2014 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for 3rd Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Tuesday, July 8, at 4:15 PM ET
![Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases
Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases.
![Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development
Cardiovascular toxicity is a significant cause of candidate failure in drug development. Pharmacokinetic/pharmacodynamic (PK/PD) modeling may reduce attrition by improving the understanding...
![Testicular distribution and toxicity of a novel LTA4H inhibitor in rats](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Testicular distribution and toxicity of a novel LTA4H inhibitor in rats
JNJ 40929837, a novel leukotriene A4 hydrolase inhibitor in drug development, was reported to induce testicular toxicity in rats.
![Synthesis and in silico studies of pyrrolidine sulfonamide based dipeptides as ß-gluscosidase inhibitors](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Synthesis and in silico studies of pyrrolidine sulfonamide based dipeptides as ß-gluscosidase inhibitors
A series of novel pyrrolidine sulfonamide derivatives were designed, synthesized and screened in silico for their β-gluscosidase inhibitory activity.
![Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically-based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically-based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction
YQA-14 is a novel and selective dopamine D3 receptor antagonist, with potential for the treatment of drug addiction. However, earlier compounds in its structural class tend to have poor oral bioavailability.